A Journal Club on Lipid Management:

Program Goals

JUPITER Increased Incidence of T2D With Rosuvastatin

Statins and New-Onset T2D Meta-Analysis of 13 Clinical Trials

T2D Risk: No Difference Between Statins

T2D Risk Increases With Statin Potency Meta-Analysis of 5 Clinical Trials

Certain Statins Increase the Risk for New-Onset T2D

Pitavastatin Does Not Adversely Affect FBG, HbA1c, or T2D Development

Pitavastatin Has Neutral Effect on FBG Across the Dose Range

J-PREDICT Study Design

J-PREDICT Primary Outcome: Cumulative Incidence of Diabetes

TNT: Risk for New-Onset T2D Stratified by Risk Factors and Statin Dose

Risk for New-Onset T2D Stratified by Age

Multidisciplinary Team Approach to Reduce Risk for Diabetes

JUPITER: CV Benefit vs T2D Risk

Statin-Associated T2D Implications for Clinical Care

How Statins Could Impair Glucose and Insulin Metabolism

Statin Selection Consideration

Abbreviations

Abbreviations (cont)